Radar›Companies›Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 5
United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 5

A five-company surgical and medical instruments and apparatus cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness
Readiness leaderPAVmed · 48
Strongest available pathWest Pharmaceutical Services · -20.2%
Widest latest marginPAVmed · 564.8%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1PAVM · Nasdaq

PAVmed

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2014New York City, New York$39.9M market cap
View full Companies Radar profile
48Cautious
Snapshot price$4.99as of page date
Monthly-close return-99.9%five-year window
FY2025 revenue$0.00BPAVmed Inc.
Net margin564.8%FY2025
P/E snapshot-2.1xone ratio, not a verdict
Prism attention13.8%share across these five
Filing track recordRevenue, USD billions
-85.8%
$0$0.0B$0.0B$0.0BFY2021: $0.001BFY2022: $0.000BFY2023: $0.002BFY2024: $0.003BFY2025: $0.000B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -38.6%
52-week position5% through range
$3.85$28.44
News mentions671
Community mentions0partial coverage
U.S.-scope patents122
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal55/100
Management stability90/100
Market position3/100
Capital-event signal67/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2LUCD · Nasdaq

Lucid Diagnostics

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2018New York City, New York$186.0M market cap
View full Companies Radar profile
47Cautious
Snapshot price$0.97as of page date
Monthly-close return-90.2%five-year window
FY2024 revenue$0.00BLucid Diagnostics Inc.
Net margin-1047.6%FY2024
P/E snapshot-5.9xone ratio, not a verdict
Prism attention11.6%share across these five
Filing track recordRevenue, USD billions
+769.2%
$0$0.0B$0.0B$0.0BFY2021: $0.001BFY2022: $0.000BFY2023: $0.002BFY2024: $0.004B2021202220232024
FY2021–FY2024 · 4 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2021 · CAGR 105.6%
52-week position14% through range
$0.86$1.63
News mentions566
Community mentions0partial coverage
U.S.-scope patents3
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal41/100
Management stability90/100
Market position21/100
Capital-event signal78/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3VTAK · NYSE

RA Medical systems

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2016Roxbury Township, New Jersey$0.7M market cap
View full Companies Radar profile
47Cautious
Snapshot price$0.20as of page date
Monthly-close return-100.0%five-year window
FY2025 revenue$0.00BCatheter Precision, Inc.
Net margin-2098.0%FY2025
Prism attention14.4%share across these five
Filing track recordRevenue, USD billions
+3622.7%
$0$0.0B$0.0B$0.0BFY2021: $0.000BFY2022: $0.000BFY2023: $0.000BFY2024: $0.000BFY2025: $0.001B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2023 · CAGR 147.0%
52-week position0% through range
$0.19$3.20
News mentions702
Community mentions0partial coverage
U.S.-scope patents67
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal50/100
Management stability90/100
Market position9/100
Capital-event signal65/100
Innovation pulse10/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4APYX · Nasdaq

Apyx Medical

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1982Dover$128.5M market cap
View full Companies Radar profile
46Cautious
Snapshot price$3.05as of page date
Monthly-close return-78.0%five-year window
FY2025 revenue$0.05BApyx Medical Corp
Net margin-21.2%FY2025
P/E snapshot-11.8xone ratio, not a verdict
Prism attention11.3%share across these five
Filing track recordRevenue, USD billions
+8.9%
$0$0.0B$0.0B$0.1BFY2021: $0.049BFY2022: $0.045BFY2023: $0.052BFY2024: $0.048BFY2025: $0.053B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.2%
52-week position40% through range
$1.70$5.08
News mentions550
Community mentions0partial coverage
U.S.-scope patents112
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal70/100
Management stability90/100
Market position0/100
Capital-event signal38/100
Innovation pulse17/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 1 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5WST · NYSE

West Pharmaceutical Services

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1923EXTON$23.83B market cap
View full Companies Radar profile
45Cautious
Snapshot price$338.6as of page date
Monthly-close return-20.2%five-year window
FY2025 revenue$3.07BWEST PHARMACEUTICAL SERVICES INC
Net margin16.1%FY2025
P/E snapshot43.4xone ratio, not a verdict
Prism attention48.9%share across these five
Filing track recordRevenue, USD billions
+8.6%
$0$1.0B$2.0B$3.1BFY2021: $2.832BFY2022: $2.887BFY2023: $2.950BFY2024: $2.893BFY2025: $3.074B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.1%
52-week position71% through range
$223.8$386.0
News mentions2.4K
Community mentions12partial coverage
U.S.-scope patents459
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal82/100
Management stability90/100
Market position8/100
Capital-event signal15/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 1 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

West Pharmaceutical Services
-20.2%
Apyx Medical
-78.0%
Lucid Diagnostics
-90.2%
PAVmed
-99.9%
RA Medical systems
-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

West Pharmaceutical Services
$3.07B
Apyx Medical
$0.05B
Lucid Diagnostics
$0.00B
RA Medical systems
$0.00B
PAVmed
$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

PAVmed
564.8%
West Pharmaceutical Services
16.1%
Apyx Medical
-21.2%
Lucid Diagnostics
-1047.6%
RA Medical systems
-2098.0%

Prism news attention

Normalized share across these five names; attention is not quality.

West Pharmaceutical Services
48.9%
RA Medical systems
14.4%
PAVmed
13.8%
Lucid Diagnostics
11.6%
Apyx Medical
11.3%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

West Pharmaceutical Services leads the conversation

It holds 48.9% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $3.07B.

Price path

West Pharmaceutical Services leads the available price paths

Its monthly-close return is -20.2% for the five-year window. At the other end, RA Medical systems is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

PAVmed has the widest latest margin

Its FY2025 net margin is 564.8%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Apyx Medical shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -11.8x while its five-year window price return is -78.0%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · WST

West Pharmaceutical Services

2,382available Prism news records

Prism top themes

Price action & investor response
198
Earnings & financial performance
119
Legal, arbitration & regulatory
77
Macro demand & rates
75
Capital allocation & transactions
70

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+110.1%603 latest 12m vs 287 prior 12m
2024-01: 20 mentions2024-02: 35 mentions2024-03: 20 mentions2024-04: 26 mentions2024-05: 20 mentions2024-06: 9 mentions2024-07: 14 mentions2024-08: 16 mentions2024-09: 21 mentions2024-10: 21 mentions2024-11: 18 mentions2024-12: 13 mentions2025-01: 20 mentions2025-02: 54 mentions2025-03: 27 mentions2025-04: 27 mentions2025-05: 32 mentions2025-06: 24 mentions2025-07: 32 mentions2025-08: 24 mentions2025-09: 30 mentions2025-10: 58 mentions2025-11: 28 mentions2025-12: 31 mentions2026-01: 72 mentions2026-02: 107 mentions2026-03: 60 mentions2026-04: 70 mentions2026-05: 71 mentions2026-06: 20 mentions2024-012026-06

Machine-classified coverage tone

91.6% positive+6.5 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

smart packaging 69anti-counterfeiting packaging 56temperature-sensitive packaging 48stock price 39drug distribution 33stock performance 32investment deal 21earnings report 20

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-07–2026-06-19 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

PAVM

PAVmed

through 2026-04-02
Earnings releases 15Company announcements 11Leadership changes 2
  1. Leadership changes

    today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's current and future medical device portfolio.

  2. Earnings releases

    GAAP net loss attributable to common stockholders was approximately $1.8 million, or $(2.05) per common share on a diluted basis.

  3. Company announcements

    PAVmed Inc. (Nasdaq: PAVM) "PAVmed" or the "Company", today announced that it will host a business update conference call and webcast on Monday, March 30, 2026, at 8:30 AM ET.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

LUCD

Lucid Diagnostics

through 2026-03-30
Earnings releases 24Company announcements 10Business contracts 3Leadership changes 2
  1. Earnings releases

    Recognized $1.5 million in EsoGuard ® Esophageal DNA Test revenue for 4Q25

  2. Business contracts

    We have entered into a Sales Agreement, or the “sales agreement,” with Maxim Group LLC, or “Maxim,” relating to shares of our common stock, up to $25,000,000

  3. Company announcements

    Conference Call and Webcast at 8:30 AM ET NEW YORK , March 12, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD ) ('Lucid' or the 'Company') a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM ), today announced that it will host a business update conference call and webcast on Thursday, March 26, 2026, at 8:30 AM ET.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

VTAK

RA Medical systems

through 2023-04-19
Leadership changes 11M&A 1
  1. Leadership changes

    Ra Medical Systems (NYSE:RMED) CEO Will McGuire this week announced his resignation from the company due to personal reasons.

  2. M&A

    Ra Medical Systems, Inc. announces the completion of its previously announced stock-for-stock merger transaction with Catheter Precision, Inc.

  3. Leadership changes

    Martin Colombatto, McGuire and Susann Meline were appointed as directors.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

APYX

Apyx Medical

through 2025-12-09
Earnings releases 36Leadership changes 4Business contracts 1Listing / IPO 1Regulatory 1
  1. Regulatory

    Apyx Medical secured regulatory approval and began the commercial launch of its Apyx One console and single use handpieces in South Korea, with initial shipments slated for Q4 2025.

  2. Listing / IPO

    Apyx Medical Corporation (Nasdaq: APYX) ... is commencing an underwritten public offering of shares of its common stock (or common stock equivalents).

  3. Earnings releases

    Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that financial results for the third quarter of fiscal year 2025 will be released before markets open on Thursday, November 6th.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

WST

West Pharmaceutical Services

through 2026-04-23
Earnings releases 42Leadership changes 8Lawsuits 3Company announcements 2Asset acquisitions 1
  1. Earnings releases

    West Pharmaceutical Services updated its Q2 2026 guidance to 2.050-2.120 EPS.

  2. Company announcements

    West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the opening of its new building at its current site in Damastown, Dublin. The 165,000 square foot expansion significantly enhances West’s contract services.

  3. Leadership changes

    West Pharmaceutical Services, Inc. (NYSE: WST) announced today that Eric M. Green has informed the Board of Directors that he plans to retire from his positions as President, Chief Executive Officer and Chair of the Board of the Company once his successor has been hired in order to ensure a smooth transition.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence
2019 extracted base$10.20B–$11.75B
2025 extracted forecast$11.50B–$21.52B
Implied source CAGR7.4%
increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records
Latest 12m volume+8.7%36648 vs 33721 records
Positive classified tone66.7%+5.2 pp vs prior four quarters
2024-01: 2,862 mentions2024-02: 2,508 mentions2024-03: 2,665 mentions2024-04: 2,848 mentions2024-05: 2,984 mentions2024-06: 2,155 mentions2024-07: 2,123 mentions2024-08: 2,108 mentions2024-09: 2,116 mentions2024-10: 2,483 mentions2024-11: 2,604 mentions2024-12: 2,045 mentions2025-01: 2,853 mentions2025-02: 5,160 mentions2025-03: 3,909 mentions2025-04: 3,553 mentions2025-05: 2,612 mentions2025-06: 1,780 mentions2025-07: 3,188 mentions2025-08: 7,906 mentions2025-09: 2,642 mentions2025-10: 2,462 mentions2025-11: 2,103 mentions2025-12: 2,450 mentions2026-01: 1,736 mentions2026-02: 4,268 mentions2026-03: 3,588 mentions2026-04: 4,213 mentions2026-05: 312 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates
7,802
medical drama series
7,076
cannabis legalization trends & economic impact
6,207
recreational marijuana usage
5,579
in-flight medical emergency protocols
4,688
medical marijuana laws & regulatory frameworks
3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

66.7% positive · +5.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 21–28. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

RA Medical systems shows a price-operating divergence to inspect

Its displayed filing-revenue change is +3622.7% while its available monthly-close return is -100.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open RA Medical systems in Companies Radar
Explanations

Attention measures coverage volume, not quality

West Pharmaceutical Services's 48.9% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open West Pharmaceutical Services in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open PAVmed's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 48/100 score.

Open PAVmed in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon